Lumos Pharma Inc (LUMO) Stock Price, Quote & News

NVDAMillionaire Jan. 25 at 11:23 PM

$LUMO Lumos Pharma Reports Promising Second Quarter 2024 Results and Provides Update on Planned Phase 3 Trial for LUM-201 https://beyondspx.com/article/lumos-pharma-lumo-navigating-the-rare-disease-landscape-with-promising-oral-therapeutics

0 · Reply

Bakhmutbull2 Dec. 13 at 4:36 PM

$LUMO Lumo and their pointless drug was just another example of private money from early lumo investers needing a vehicle to escape when they grabbed newlink genetics and their $115 million cash pile. 6 bagger off the bottom and left for trash sweepers.

1 · Reply

Scanners_Free Dec. 12 at 1:48 PM

$LUMO NNEEEEEEWSSSSSS

0 · Reply

tradingcalendar Dec. 11 at 9:07 PM

Two acquisitions closing, to be delisted tonight after the close of extended hours trading - $AY to be acquired by Energy Capital Partners, $22.00 cash - $LUMO to be acquired by Double Point Ventures, $4.25 cash + 1 CVR More Info : https://www.sec.gov/Archives/edgar/data/1601072/000114036124045048/ef20038091_ex99-1.htm https://www.sec.gov/Archives/edgar/data/1126234/000119312524268141/d880311dsc14d9a.htm

0 · Reply

belugatrade Dec. 5 at 8:08 PM

$LUMO ⏲️

0 · Reply

Joe_Mama Dec. 5 at 1:46 PM

$LUMO Closed my position for a loss. Not happy about it. I do hate this company now.

1 · Reply

Bronsma Nov. 27 at 9:04 PM

$LUMO Anyone have a feel for the trading behavior on this? Seems to be a huge amount of selling built up around $4.32. is it large positions selling out rather than tendering, or is it something more nefarious?

0 · Reply

NVDAMillionaire Nov. 22 at 6:39 AM

$LUMO Lumos Pharma (LUMO): Navigating the Rare Disease Landscape with Promising Oral Therapeutics https://beyondspx.com/article/lumos-pharma-lumo-navigating-the-rare-disease-landscape-with-promising-oral-therapeutics

0 · Reply

Investor203 Nov. 18 at 1:59 PM

$LUMO y showing $0

0 · Reply

Investor203 Nov. 8 at 6:01 PM

$TSLA holding till $350. $VSTM and $LUMO next on my list.

0 · Reply

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma

Oct 23, 2024, 3:51 PM EDT - 9 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.

Oct 23, 2024, 3:31 PM EDT - 9 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders

MMLP

Sep 25, 2024, 4:05 PM EDT - 10 months ago

Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024

Aug 15, 2024, 9:00 AM EDT - 11 months ago

Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 9:30 PM EDT - 1 year ago

Lumos Pharma, Inc. (LUMO) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update

Jul 23, 2024, 4:05 PM EDT - 1 year ago

Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024

May 20, 2024, 4:05 PM EDT - 1 year ago

Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024

May 15, 2024, 3:10 PM EDT - 1 year ago

Lumos Pharma, Inc. (LUMO) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:15 PM EDT - 1 year ago

Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results

May 9, 2024, 2:51 PM EDT - 1 year ago

Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024

Apr 18, 2024, 4:05 PM EDT - 1 year ago

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

Mar 20, 2024, 8:00 AM EDT - 1 year ago

Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042

Mar 7, 2024, 5:45 PM EST - 1 year ago

Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:01 PM EST - 1 year ago

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

Feb 26, 2024, 9:00 AM EST - 1 year ago

Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

Feb 5, 2024, 4:05 PM EST - 1 year ago

Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference

Jan 4, 2024, 4:05 PM EST - 1 year ago

Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

Nov 21, 2023, 4:15 PM EST - 1 year ago

Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

Nov 20, 2023, 4:05 PM EST - 1 year ago

Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November

Nov 7, 2023, 4:35 PM EST - 1 year ago

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

Nov 7, 2023, 4:01 PM EST - 1 year ago

Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints

Sep 26, 2023, 9:00 AM EDT - 1 year ago

Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting

Sep 14, 2023, 8:00 AM EDT - 1 year ago

Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting

Sep 7, 2023, 4:34 PM EDT - 1 year ago

Lumos Pharma Announces Participation in Investor Conferences in September

Aug 22, 2023, 9:00 AM EDT - 2 years ago

Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape

Aug 9, 2023, 10:27 PM EDT - 2 years ago

Lumos Pharma, Inc. (LUMO) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 4:01 PM EDT - 2 years ago

Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update

Jul 26, 2023, 9:00 AM EDT - 2 years ago

Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023

Jul 12, 2023, 8:00 AM EDT - 2 years ago

Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit

Jun 28, 2023, 4:01 PM EDT - 2 years ago

Lumos Pharma Announces Departure of Chief Medical Officer

Jun 21, 2023, 9:00 AM EDT - 2 years ago

Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

May 25, 2023, 8:00 AM EDT - 2 years ago

Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st

May 3, 2023, 4:05 PM EDT - 2 years ago

Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates

Apr 27, 2023, 9:00 AM EDT - 2 years ago

Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)

Apr 19, 2023, 9:00 AM EDT - 2 years ago

Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

Mar 5, 2023, 2:00 PM EST - 2 years ago

Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology

Mar 1, 2023, 9:37 PM EST - 2 years ago

Lumos Pharma, Inc. (LUMO) Q4 2022 Earnings Call Transcript

Mar 1, 2023, 4:05 PM EST - 2 years ago

Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates

Feb 28, 2023, 4:05 PM EST - 2 years ago

Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD

Feb 15, 2023, 4:05 PM EST - 2 years ago

Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023

Jan 3, 2023, 9:00 AM EST - 2 years ago

Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023

Dec 12, 2022, 7:30 AM EST - 2 years ago

KOL Review of Lumos Pharma's Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients

Nov 29, 2022, 4:05 PM EST - 2 years ago

Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

Nov 22, 2022, 4:05 PM EST - 2 years ago

Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 14, 2022, 6:10 AM EST - 2 years ago

Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates

Nov 14, 2022, 6:00 AM EST - 2 years ago

Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency

NVDAMillionaire Jan. 25 at 11:23 PM

0 · Reply

Bakhmutbull2 Dec. 13 at 4:36 PM

1 · Reply

Scanners_Free Dec. 12 at 1:48 PM

$LUMO NNEEEEEEWSSSSSS

0 · Reply

tradingcalendar Dec. 11 at 9:07 PM

0 · Reply

belugatrade Dec. 5 at 8:08 PM

$LUMO ⏲️

0 · Reply

Joe_Mama Dec. 5 at 1:46 PM

$LUMO Closed my position for a loss. Not happy about it. I do hate this company now.

1 · Reply

Bronsma Nov. 27 at 9:04 PM

0 · Reply

NVDAMillionaire Nov. 22 at 6:39 AM

0 · Reply

Investor203 Nov. 18 at 1:59 PM

$LUMO y showing $0

0 · Reply

Investor203 Nov. 8 at 6:01 PM

$TSLA holding till $350. $VSTM and $LUMO next on my list.

0 · Reply

Investor203 Nov. 7 at 3:45 PM

$EBS $CHRS $GRI $LUMO to watch for next 2-3 weeks.

0 · Reply

Investor203 Nov. 7 at 3:03 PM

$EBS $LUMO is free money with $4.25 BO offer and 3 years potential premium on the milestones upto $7.

0 · Reply

Investor203 Nov. 6 at 6:16 PM

$LUMN $LUMO ❤️‍🔥

0 · Reply

Investor203 Nov. 5 at 5:11 PM

$ALAB should buy $LUMO

0 · Reply

Investor203 Nov. 1 at 12:38 PM

$ARDX $LUMO might get counter offer for BO. Keep and eye

1 · Reply

Thestocktraderhubzee Oct. 25 at 4:20 AM

WATCHLIST OCT 25 2024 $ARE RBC Capital Downgrades Alexandria Real Estate to Sector Perform, Lowers Price Target to $125 $PHAR HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target $LUMO HC Wainwright & Co. Downgrades Lumos Pharma to Neutral, Lowers Price Target to $4.25 $NEE Guggenheim Maintains Buy on NextEra Energy, Raises Price Target to $92 $GSHD JMP Securities Maintains Market Outperform on Goosehead Insurance, Raises Price Target to $115

1 · Reply

Investor203 Oct. 24 at 11:15 AM

$VKTX $LUMO to the moon.

0 · Reply

cdlawton07 Oct. 23 at 2:49 PM

$LUMO Last I knew 3 men, Rick Hawkins, Kevin LaLande and Harry Stein held 30% of all shares outstanding. They say 17% of all shares outstanding agree to tender for the deal. Do we have a big shareholder not too keen on the deal?

1 · Reply

Investor203 Oct. 23 at 1:39 PM

$LUMO will buy 20,000 shares if it gores $4.25 or below.

0 · Reply

YoloAlfred Oct. 23 at 1:25 PM

$LUMO $MGNI why $6 when offer is $4.25

1 · Reply

Investor203 Oct. 23 at 1:23 PM

$MGNI $LUMO should be $6 with the news

0 · Reply

Stocks4thought Oct. 23 at 1:12 PM

$LUMO That was dumb- nobody wanting that cheap of a price.

1 · Reply

Market Cap	37.54M
Revenue (ttm)	2.05M
Net Income (ttm)	-34.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,660.00%
Debt to Equity Ratio	0.00

Volume	481,600
Avg Vol	108,584
Day's Range	N/A - N/A
Shares Out	8.65M
Stochastic %K	40%
Beta	0.74
Analysts	Sell
Price Target	$8.17